SLNO — Soleno Therapeutics, Inc.

Summary of Soleno Therapeutics Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Net Revenue: $66 million, more than double from $32.7 million in Q2 2025.
• Net Income: $26 million, translating to $0.49 per basic share and $0.47 per diluted share, a significant turnaround from a net loss of $76.6 million in Q3 2024.
• Cash Flow: Generated $43.5 million from operating activities; cash, cash equivalents, and marketable securities totaled $556.1 million at quarter-end.
• Cost of Goods Sold: $1.1 million, with expectations that this will increase as inventory costs normalize.
• R&D Expenses: $8.4 million, down from $30.1 million in Q3 2024, reflecting reduced clinical trial costs.
• SG&A Expenses: $33.8 million, down from $49.2 million in Q3 2024, indicating operational efficiency improvements.

2. Strategic Updates and Business Highlights

• Product Launch: VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome (PWS), has seen strong adoption with 764 active patients and 1,043 cumulative patient start forms.
• Market Access: Secured coverage for approximately 132 million lives, including broad access across commercial, Medicaid, and Medicare channels.
• Patient Education Initiatives: Enhanced outreach through community events and physician education programs to support the integration of VYKAT XR into clinical practice.
• European Expansion: Progressing with the EMA for DCCR (VYKAT XR) approval, with responses to regulatory questions expected soon.

3. Forward Guidance and Outlook

• The company is optimistic about continued growth in patient adoption and revenue, with plans to further educate healthcare providers and patients.
• While the company has not provided specific annual revenue guidance, they are monitoring market dynamics closely and expect to mature their business components before issuing guidance.

4. Bad News, Challenges, or Points of Concern

• Impact of Short Seller Report: The company experienced a disruption in launch momentum due to a short seller report in August, leading to decreased patient start forms and increased discontinuations, particularly among patients experiencing non-serious adverse events.
• Discontinuation Rates: The discontinuation rate rose to approximately 10%, with 8% attributed to adverse events, though this remains below long-term expectations.
• Market Education: There is a need for ongoing education for prescribers, particularly those less experienced with PWS, to mitigate concerns about adverse events and improve patient retention.

5. Notable Q&A Insights

• Restart Rates: Early indications show some patients are beginning to restart therapy after discontinuation, but specific metrics are still developing.
• Patient Coverage Delays: The average time for insurance clearance post-start form submission is approximately 30 days, indicating a backlog that could affect future patient numbers.
• Efficacy Anecdotes: Positive patient experiences are being reported, which may help reduce discontinuation rates over time.
• Competitive Landscape: The potential for synergy with Rhythm's drug for PWS was discussed, but the efficacy of Rhythm's treatment remains uncertain following a negative Phase II study.

Overall, Soleno Therapeutics reported a strong quarter with significant revenue growth and a positive outlook for VYKAT XR, despite facing challenges related to market education and the impact of external reports on patient uptake.